Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Generalized myasthenia gravis

Launch
Not announced
Last updated
120 sources

Section 3 of 6

Product information and disease description

242 evidence topics · 102 sources

Product description

Phase of product development

Launch

No evidence found.

Fast track or breakthrough therapy designation for generalized myasthenia gravis

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Brand name

No evidence found.

Dosage forms and strengths
Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
AHFS class and ATC code assigned to claseprubart

No evidence found.

Indication
Pharmacology
Mechanism of action
Pharmacodynamics
In vitro affinity and potency compared with riliprubart
AssayClaseprubart (DNTH103)Riliprubart
Binding affinity to human active C1s, KD (KinExa)“9pM”“75pM”
Binding affinity to human active C1s, KD (SPR)“8pM”“35pM”
C4 cleavage by human active C1s, IC90 (nM)“0.47”“3.69”
Wieslab classical pathway assay in human serum, IC90 (μg/mL)“0.45”“5.4”
CH50 assay of RBC lysis in human serum, IC90 (μg/mL)“98”“668”
Liposome lysis in human serum, IC90 (μg/mL)“14.7”“39.8”
Pharmacokinetics
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Special populations
Drug/Drug, drug/disease interactions
Effects of other drugs on Claseprubart
Effects of Claseprubart on other drugs

No evidence found.

Dosing and administration
Dosage
Administration
Access and distribution
Co-prescribed/Concomitant therapies
Background immunosuppressive therapy at baseline in the phase 2 trial
CharacteristicPlacebo (N=22)Claseprubart 300 mg every 2 weeks (N=21)Claseprubart 600 mg every 2 weeks (N=22)
Baseline corticosteroid use, n (%)“19 (86%)”“17 (81%)”“20 (91%)”
Number of immunosuppressive therapies at baseline: 1, n (%)“11 (50%)”“10 (48%)”“12 (55%)”
Number of immunosuppressive therapies at baseline: more than 1, n (%)“11 (50%)”“11 (52%)”“10 (45%)”
Neonatal Fc receptor blocker use in prior 24 months, n (%)“0 (0%)”“1 (5%)”“0 (0%)”
Prior complement inhibitor use, n (%)“0 (0%)”“0 (0%)”“0 (0%)”
Prior thymectomy, n (%)“8 (36%)”“6 (29%)”“7 (32%)”
Effect of Claseprubart on quality measures

No evidence found.

Product comparison

Place of product in therapy

Disease description

Definition and etiology
Definition: autoantibody-mediated disorder of neuromuscular transmission
Epidemiology
Incidence of Generalized myasthenia gravis
Prevalence of Generalized myasthenia gravis
Natural history, survival, and mortality
Mortality and survival: United States Medicare beneficiaries aged 65 years and older
Pathophysiology
AChR antibodies: complement fixation, antigenic modulation, and receptor blockade
Diagnosis
Clinical presentation - signs and symptoms
Long-term morbidity
Myasthenic crisis: frequency, triggers, and outcomes
Glucocorticoid toxicity: United States commercially insured adults with generalized myasthenia gravis

“Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (≥5 mg/d: 1537 [40.9%]; ≥10 mg/d: 860 [22.9%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“During the study period, incident GC toxicities were more common among patients in the any GC use cohort than the no GC use cohort (61.9% vs 52.3% with ≥1 toxicity), with a trend of increasing incidence with increasing GC use (≥5 mg/d: 62.9%; ≥10 mg/d: 67.3%; all P < .001” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Additionally, a greater proportion of patients with any GC use than no GC use had ≥3 incident GC toxicities (16.5% vs 9.5%), with this proportion rising with mean PEDD ≥5 mg (18.9%) and mean PEDD ≥10 mg (22.8%; all P <.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Both acute and chronic incident GC toxicities were more common in the any GC use cohort than the no GC use cohort (acute: 28.5% vs 19.1%; chronic: 51.9% vs 43.8%; both P <.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Common acute toxicities included nausea and vomiting, pneumonia, fungal infections, sepsis, and urinary tract infection; chronic toxicities were dyslipidemia, sleep disturbances, obesity, cardiac arrhythmias, and hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Since claims data do not contain reasons for diagnoses, toxicities could not be confirmed to be related to GC use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Burden of Generalized myasthenia gravis
Humanistic burden and health-related quality of life
Economic burden and healthcare resource utilization
Range of direct and indirect costs across studies: systematic reviews
Economic impact of Generalized myasthenia gravis on families
Economic impact of diagnostic testing

Approaches to treatment

Current treatment options and standard of care
Acetylcholinesterase inhibitors
Corticosteroids
Nonsteroidal immunosuppressive agents
Indications for and choice of nonsteroidal immunosuppressive agents: international consensus guidance

“A nonsteroidal IS agent should be used alone when corticosteroids are contraindicated or refused. A nonsteroidal IS agent should be used initially in conjunction with corticosteroids when the risk of steroid side effects is high based on medical comorbidities. A nonsteroidal IS agent should be added to corticosteroids when: a. Steroid side effects, deemed significant by the patient or the treating physician, develop; b. Response to an adequate trial (table e-1) of corticosteroids is inadequate; or c. The corticosteroid dose cannot be reduced due to symptom relapse.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Nonsteroidal IS agents that can be used in MG include azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, and tacrolimus. The following factors should be considered in selecting among these agents: a. There is widespread variation in practice with respect to choice of IS agent since there is little literature comparing them. b. Expert consensus and some RCT evidence support the use of azathioprine as a first-line IS agent in MG. c. Evidence from RCTs supports the use of cyclosporine in MG, but potential serious adverse effects and drug interactions limit its use. d. Although available RCT evidence does not support the use of mycophenolate and tacrolimus in MG, both are widely used, and one or both are recommended in several national MG treatment guidelines” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For nonsteroidal IS agents, once treatment goals have been achieved and maintained for 6 months to 2 years, the IS dose should be tapered slowly to the minimal effective amount.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Thymectomy
Intravenous immunoglobulin and plasma exchange
Complement c5 inhibitors
Neonatal fc receptor blockers
B-cell depleting antibodies
Limitations of current therapies
Summary

10% to 20% of patients continue to have long-standing moderate or severe weakness after treatment with at least two different immunosuppressive drugs at high doses, and Tice et al. (2022) state that about 20,000 patients with generalized myasthenia gravis are estimated to be intolerant or to have an inadequate response to conventional treatment options. Upward of thirty percent of patients do not benefit from complement inhibition. In claims data from 8833 patients with generalized myasthenia gravis, incident glucocorticoid toxicities occurred in 61.9% of patients with any glucocorticoid use, compared with 52.3% without, and annual all-cause costs were more than twice as high ($76,381 vs $35,309). Soliris increases the risk of serious meningococcal infections, requires meningococcal vaccination at least 2 weeks before the first dose, and, like Zilbrysq, is available only through a REMS program. Vyvgart may increase the risk of infection. Gilhus et al. list the need for meningococcal vaccination before starting treatment, recommended pneumococcal vaccination, and regular intravenous or subcutaneous injections as limitations, and a company presentation states that 40% of patients discontinue Vyvgart within one year. ICER estimated an incremental cost-effectiveness ratio of $5,210,000 per QALY/evLYG for eculizumab, and high drug costs limit access to complement inhibitors and FcRn blockers in most countries.

Meningococcal infection risk, vaccination, and REMS with complement C5 inhibitors
Cost and cost-effectiveness of targeted biologics
Place in treatment, anticipated use, and care setting
Summary

The roles of complement and FcRn inhibitors are being established, especially in patients unresponsive to conventional therapy; Gilhus et al. (2024) recommend them, because of high drug costs, only for difficult-to-treat patients with severe myasthenia gravis not responding to standard immunosuppressive treatment, and as second- or third-line treatment in severe exacerbations and crisis. The company positions claseprubart as a potential first-line biologic intended to displace C5 complement inhibitors and compete with FcRn blockers, and notes that the C5 efficacy data it compares against come from different trials with different designs and populations. Its target profile is a single self-administered 300 mg/2 mL subcutaneous autoinjector dosed every 2 or 4 weeks, without a boxed warning or REMS; the every-4-week arm and a QMG inclusion criterion were added to the phase 3 trial after a post hoc analysis of MaGic. The company proposes that selective inhibition of the classical pathway may lower the risk of infection from encapsulated bacteria by preserving the lectin and alternative pathways.

Heterogeneity of treatment effect
Inebilizumab effect by antibody status
Week 26 outcomeOverall populationAnti-AChR antibody positiveAnti-MuSK antibody positive
MG-ADL difference from placebo“-1.9”“-1.8”“-2.2”
MG-ADL p-value“<0.0001”“0.0015”“0.0297”
QMG difference from placebo“-2.5”“-2.5”“-2.3”
QMG p-value“0.0002”“0.0011”“NS”
Care management intervention strategies
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy